110 related articles for article (PubMed ID: 15261433)
1. Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma.
O'Byrne KJ; Edwards JG; Waller DA
Lung Cancer; 2004 Aug; 45 Suppl 1():S45-8. PubMed ID: 15261433
[TBL] [Abstract][Full Text] [Related]
2. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
Edwards JG; Swinson DE; Jones JL; Waller DA; O'Byrne KJ
Lung Cancer; 2006 Dec; 54(3):399-407. PubMed ID: 17049671
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.
Edwards JG; Faux SP; Plummer SM; Abrams KR; Walker RA; Waller DA; O'Byrne KJ
Clin Cancer Res; 2002 Jun; 8(6):1857-62. PubMed ID: 12060628
[TBL] [Abstract][Full Text] [Related]
4. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
[TBL] [Abstract][Full Text] [Related]
5. Molecular prognostic markers in malignant mesothelioma.
Kumar P; Kratzke RA
Lung Cancer; 2005 Jul; 49 Suppl 1():S53-60. PubMed ID: 15950802
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma.
O'Kane SL; Cawkwell L; Campbell A; Lind MJ
Eur J Cancer; 2005 Jul; 41(11):1645-8. PubMed ID: 15964184
[TBL] [Abstract][Full Text] [Related]
7. EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
Kothmaier H; Quehenberger F; Halbwedl I; Morbini P; Demirag F; Zeren H; Comin CE; Murer B; Cagle PT; Attanoos R; Gibbs AR; Galateau-Salle F; Popper HH
Thorax; 2008 Apr; 63(4):345-51. PubMed ID: 18086752
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
[TBL] [Abstract][Full Text] [Related]
9. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
Destro A; Ceresoli GL; Falleni M; Zucali PA; Morenghi E; Bianchi P; Pellegrini C; Cordani N; Vaira V; Alloisio M; Rizzi A; Bosari S; Roncalli M
Lung Cancer; 2006 Feb; 51(2):207-15. PubMed ID: 16384623
[TBL] [Abstract][Full Text] [Related]
10. [Clinico-pathological prognostic factors in malignant pleural mesothelioma].
Nakano K; Shiota Y; Ono T; Taniyama K; Hiramoto T; Yamakido M
Nihon Kokyuki Gakkai Zasshi; 2007 Feb; 45(2):153-9. PubMed ID: 17352172
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer.
Koga T; Shibahara K; Kabashima A; Sumiyoshi Y; Kimura Y; Takahashi I; Kakeji Y; Maehara Y
Hepatogastroenterology; 2004; 51(60):1626-30. PubMed ID: 15532792
[TBL] [Abstract][Full Text] [Related]
12. The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Cole GW; Alleva AM; Reddy RM; Maxhimer JB; Zuo J; Schrump DS; Nguyen DM
J Thorac Cardiovasc Surg; 2005 May; 129(5):1010-7. PubMed ID: 15867774
[TBL] [Abstract][Full Text] [Related]
13. May cyclooxygenase-2 (COX-2), p21 and p27 expression affect prognosis and therapeutic strategy of patients with malignant pleural mesothelioma?
Mineo TC; Ambrogi V; Cufari ME; Pompeo E
Eur J Cardiothorac Surg; 2010 Sep; 38(3):245-52. PubMed ID: 20338775
[TBL] [Abstract][Full Text] [Related]
14. Biological markers and prognosis in recurrent oral cancer after salvage surgery.
Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP
Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125
[TBL] [Abstract][Full Text] [Related]
15. Reactivity of integrin-linked kinase in human mesothelial cell proliferation.
Watzka SB; Setinek U; Huber M; Cantonati H; Lax F; Watson S; Weigel G; Müller MR
Interact Cardiovasc Thorac Surg; 2008 Feb; 7(1):107-10. PubMed ID: 18048409
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma.
Kumar-Singh S; Vermeulen PB; Weyler J; Segers K; Weyn B; Van Daele A; Dirix LY; Van Oosterom AT; Van Marck E
J Pathol; 1997 Jun; 182(2):211-6. PubMed ID: 9274533
[TBL] [Abstract][Full Text] [Related]
17. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches.
Scartozzi M; Galizia E; Freddari F; Berardi R; Cellerino R; Cascinu S
Cancer Treat Rev; 2004 Aug; 30(5):451-9. PubMed ID: 15245777
[TBL] [Abstract][Full Text] [Related]
18. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma.
Kobashi Y; Matsushima T; Irei T
Respirology; 2005 Nov; 10(5):660-5. PubMed ID: 16268922
[TBL] [Abstract][Full Text] [Related]
20. Biology and management of malignant pleural mesothelioma.
Zucali PA; Giaccone G
Eur J Cancer; 2006 Nov; 42(16):2706-14. PubMed ID: 16989994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
